Methods and rationale for the early detection of pancreatic cancer

Journal of the Pancreas

Volumn 11, Issue 2, 2010, Pages 128-130

  Bussom, Scott ^a   Saif, Muhammad Wasif ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE CANCER CENTER   (United States)

Author keywords

Early detection of cancer; Endosonography; Mucin 1; Mucins; Pancreatic neoplasms

Indexed keywords

BIOLOGICAL MARKER; BRCA1 PROTEIN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 1; DUPAN 2; GROWTH DIFFERENTIATION FACTOR 15; K RAS PROTEIN; MONOCLONAL ANTIBODY; MUCIN 1; PROTEIN PAM4; PROTEIN SPAN1; UNCLASSIFIED DRUG;

ADENOMATOUS POLYP; ALCOHOL CONSUMPTION; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CANCER SURGERY; CHRONIC PANCREATITIS; COLORECTAL CANCER; CONFERENCE PAPER; CYSTIC FIBROSIS; DIABETES MELLITUS; DIET; DIET THERAPY; DNA METHYLATION; EARLY DIAGNOSIS; ECHOGRAPHY; EVIDENCE BASED MEDICINE; FAMILY HISTORY; FRUIT; GENDER; GENE MUTATION; GENETIC DISORDER; GENETIC PREDISPOSITION; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HETEROZYGOTE; HIGH RISK POPULATION; HUMAN; LIFESTYLE; OBESITY; PALPATION; PANCREAS CANCER; RACE; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SEROLOGY; SMOKING; SMOKING CESSATION; VALIDATION PROCESS; VEGETABLE;

ANTIBODIES, MONOCLONAL; CARCINOMA; CONGRESSES AS TOPIC; EARLY DETECTION OF CANCER; GASTROINTESTINAL NEOPLASMS; HUMANS; IMMUNOENZYME TECHNIQUES; NEOPLASM STAGING; PANCREATIC NEOPLASMS; RATIONALIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 77749260561     PISSN: None     EISSN: 15908577     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (21)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer Statistics, 2009. CA Cancer J Clin 2009; 59:225-49. [PMID 19474385]
2. Geer RJ, Brennan MF. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg 1993; 165:68-72. [PMID 8380315]
3. Ariyama J, Suyama M, Satoh K, Sai J. Imaging of small pancreatic ductal adenocarcinoma. Pancreas 1998; 16:396-40. [PMID 9548685]
4. Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS. National failure to operate on early stage pancreatic cancer. Ann Surg 2007; 246:173-80. [PMID 17667493]
5. Agency for Healthcare Research and Quality (AHRQ). Screening for Pancreatic Cancer. Recommendation Statement. U.S. Department of Health & Human Services Washington, DC, USA, 2004.
6. Andrén-Sandberg A. 4th international symposium on inherited diseases of the pancreas. November 7-9, 2003, Chicago, Ill., USA. Pancreatology 2003; 3:520-32. [PMID 14752237]
7. Brand RE, Lerch MM, Rubinstein WS, Neoptolemos JP, Whitcomb DC, Hruban RH, et al. Advances in counselling and surveillance of patients at risk for pancreatic cancer. Gut 2007; 56:1460-9. [PMID 17872573]
8. Poley JW, Kluijt I, Gouma DJ, Harinck F, Wagner A, Aalfs C, et al. The yield of first-time endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer. Am J Gastroenterol 2009; 104:2175-81. [PMID 19491823]
9. Gold DV, Goggins M, Newsome G, Modrak DE, Liu M, Goldenberg DM. The PAM4 serum enzyme immunoassay (EIA) for detection of early-stage pancreatic carcinoma. 2010 ASCO Gastrointestinal Cancers Symposium. Abstract No. 135.
10. Gold DV, Lew K, Maliniak R, Hernandez M, Cardillo T. Characterization of monoclonal antibody PAM4 reactive with a pancreatic cancer mucin. Int J Cancer 1994; 57:204-10. [PMID 7512537]
11. Gold DV, Karanjawala Z, Modrak DE, Goldenberg DM, Hruban RH. PAM4-reactive MUC1 is a biomarker for early pancreatic adenocarcinoma. Clin Cancer Res 2007; 13:7380-7. [PMID 18094420]
12. Gold D, Modrak DE, Newsome G, Karanjawala Z, Hruban R, Goggins M, Goldenberg DM. Detection of early-stage pancreatic carcinoma. J Clin Oncol 2009; 27(15 Suppl):Abstract 4613.
13. Gold DV, Modrak DE, Ying Z, Cardillo TM, Sharkey RM, Goldenberg DM. New MUC1 serum immunoassay differentiates pancreatic cancer from pancreatitis. J Clin Oncol 2006; 24:252-8. [PMID 16344318]
14. Ni XG, Bai XF, Mao YL, Shao YF, Wu JX, Shan Y, et al. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. Eur J Surg Oncol 2005; 31:164-9. [PMID 15698733]
15. Simeone DM, Ji B, Banerjee M, Arumugam T, Li D, Anderson MA, et al. CEACAM1, a novel serum biomarker for pancreatic cancer. Pancreas 2007; 34:436-43. [PMID 17446843]
16. Kiriyama S, Hayakawa T, Kondo T, Shibata T, Kitagawa M, Ono H, Sakai Y. Usefulness of a new tumor marker, Span-1, for the diagnosis of pancreatic cancer. Cancer 1990; 65:1557-61. [PMID 2311067]
17. Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol 2007; 33:266-70. [PMID 17097848]
18. Koopmann J, Rosenzweig CN, Zhang Z, Canto MI, Brown DA, Hunter M, et al. Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9. Clin Cancer Res 2006; 12:442-6. [PMID 16428484]
19. Ishizone S, Yamauchi K, Kawa S, Suzuki T, Shimizu F, Harada O, et al. Clinical utility of quantitative RT-PCR targeted to alpha1,4-N- acetylglucosaminyltransferase mRNA for detection of pancreatic cancer. Cancer Sci 2006; 97:119-26. [PMID 16441422]
20. Matsubayashi H, Canto M, Sato N, Klein A, Abe T, Yamashita K, et al. DNA methylation alterations in the pancreatic juice of patients with suspected pancreatic disease. Cancer Res 2006; 66:1208-17. [PMID 16424060]
21. Wu X, Lu XH, Xu T, Qian JM, Zhao P, Guo XZ, Yang XO, Jiang WJ. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer. Chin J Dig Dis 2006; 7:170-4. [PMID 16808798]